Ori is supporting the heroes of cell and gene therapy who are rewriting human history.
Meet with Jason C. Foster to learn how Ori is setting the new standard for CGT manufacturing to accelerate product development and scale
Today, only a small percentage of patients are able to access lifesaving cell and gene therapies.
These therapies are too hard to manufacture,
Too expensive to make widely available,
And not commercially viable due to high costs, low throughput, and lack of reproducibility.
Together, we are on a mission to change that.
Ori is empowering scientists with flexible tools that streamline development and help to enable widespread patient access to life-saving cell and gene therapies. Historically, scientists have had to compromise biological performance for automation. With IRO®, there is no trade-off. Offering both flexibility and scalability, IRO® supports accelerated development, minimizes batch failures, increases throughput, and reduces costs.
To enable widespread patient access to lifesaving cell and gene therapies, you need both superior biological performance and the benefits of digitally enabled automation to maximize your clinical and commercial impact.
Ori has taken a biology-first approach understanding that cell quality, potency, and yield are critical to successful patient outcomes.
By automating manual steps and deskilling processes, Ori enables high throughput, high quality, and lower-cost manufacturing essential to reach scale and maximize both clinical and commercial impact.
The cloud-native Ori platform helps to accelerate process development, reduce batch failures, and streamline batch release, resulting in shorter development times and more efficient manufacturing.
United in our mission to enable widespread patient access
Farlan Veraitch, PhD
Founder and Chief Scientific Officer
Jason C. Foster, MBA
Chief Executive Officer
Thomas Heathman, PhD
Chief Commercial Officer
John Machulski
Chief Operating Officer
Stuart Milne, PhD
Chief Technology Officer
Arman Amini, PhD
Director of Bioprocessing
Leonor Monteiro
Senior Vice President, Finance
Maria O’Callaghan
Director of Product Management
Sarah Parsons
Associate Director of HR
William Raimes, PhD
Head of Process Development
Moeko Saito
Associate Director, Project Management
Matt Todd
Director of Digital Solutions
Lee Unroe
Vice President, Marketing
The latest learnings, opinions, and events
Patient Access Tracker
Ori has calculated the number of patients treated with commercially …
Read more
Ori Biotech and Charles River Laboratories Collaborate to Accelerate Life-Saving Cell and Gene Therapy Development and Manufacturing
September 18, 2024 – New Biological Data Released from IRO® …
Read more
Ori Biotech and CTMC Present Scientific Data for New IRO® Platform at ISCT 2024
June 3, 2024 – Ori LEAP partner CTMC shares biological …
Read more
Ori Biotech Unveils IRO Platform at Annual International Society for Cell & Gene Therapy Conference
May 29, 2024 – Innovative cell therapy manufacturing platform moving …
Read more
Let’s enable widespread patient access, together.
"*" indicates required fields
Oribiotech Ltd 2024 © All rights reserved.
Oribiotech Ltd is registered in England and Wales. "Ori”, “Ori Biotech”, "Iro" and the O icon are registered trademarks of Oribiotech Ltd.
Company registration 09757696.
